Mediclinic Southern Africa Site Visit and Trading Update

Mediclinic International plc, a diversified private healthcare services group, will host a site visit for analysts and institutional investors today in Cape Town, South Africa.

Koert Pretorius, Mediclinic Southern Africa’s CEO, will briefly present an overview of the division, focusing on the following areas:

− delivery against the Mediclinic International Group strategic goals;
− continued improvements in clinical performance, patient experience, employee engagement and B-BBEE scorecard;
− advancing the co-located day case clinic strategy;
− navigating the regulatory environment; and
− delivering incremental growth in Southern Africa.

Mediclinic Southern Africa has continued its good trading performance during the year and now expects FY20 revenue growth of around 6.5%.

EBITDA margin guidance for FY20 remains unchanged. In line with the Group’s strategic objectives and a continued focus on improving clinical quality and patient experience, further investment will be made in employees and information communication technology during FY20. This, together with the expected lower margin contribution from Intercare and the ramp-up of the new Mediclinic Stellenbosch facility, is anticipated to result in a pre-IFRS16 EBITDA margin of around 20%.

No new material information will be provided during the event. Presentation material will be made available online shortly after 07:00 GMT at https://ir.mediclinic.com/results-centre/presentations-and-investor-days.

About Mediclinic International plc

Mediclinic is an international private healthcare services group, established in South Africa in 1983, with divisions in Switzerland, Southern Africa (South Africa and Namibia) and the United Arab Emirates.

The Group’s core purpose is to enhance the quality of life.

Its vision is to be the partner of choice that people trust for all their healthcare needs.

Mediclinic is focused on providing specialist-orientated, multi-disciplinary services across the continuum of care in such a way that the Group will be regarded as the most respected and trusted provider of healthcare services by patients, medical practitioners, funders and regulators of healthcare in each of its markets.
As at 30 November 2019, Mediclinic comprised 77 hospitals, five sub-acute hospitals, 13 day case clinics and 22 outpatient clinics. Hirslanden operated 17 hospitals, two day case clinics and three outpatient clinics in Switzerland with more than 1 900 inpatient beds; Mediclinic Southern Africa operations included 53 hospitals (three of which in Namibia), five sub-acute hospitals and nine day case clinics (four of which operated by Intercare) across South Africa, and more than 8 500 inpatient beds; and Mediclinic Middle East operated seven hospitals, two day case clinics and 19 outpatient clinics with more than 900 inpatient beds in the United Arab Emirates.

The Company’s primary listing is on the London Stock Exchange (“LSE”) in the United Kingdom, with secondary listings on the JSE Ltd (“JSE”) in South Africa and the Namibian Stock Exchange (“NSX”) in Namibia.

Mediclinic also holds a 29.9% interest in Spire Healthcare Group plc, a leading private healthcare group based in the United Kingdom and listed on the LSE.

For further information, please contact:

**Investor Relations, Mediclinic International plc**
James Arnold, Head of Investor Relations
ir@mediclinic.com
+44 (0)20 3786 8181

**Media queries**
FTI Consulting
Ben Atwell/Ciara Martin – United Kingdom
+44 (0)20 3727 1000
Sherryn Schooling – South Africa
+27 (0)21 487 9000

**Registered address**: 6th Floor, 65 Gresham Street, London, EC2V 7NQ, United Kingdom
**Website**: www.mediclinic.com
**Joint corporate brokers**: Morgan Stanley & Co International plc and UBS Investment Bank
**JSE sponsor (South Africa)**: Rand Merchant Bank (A division of FirstRand Bank Limited)
**NSX sponsor (Namibia)**: Simonis Storm Securities (Pty) Ltd